Gynecomastia is a common adverse outcome of bicalutamide (Casodex) therapy that will prompt some Adult men to discontinue prostate cancer treatment. Tamoxifen has long been recommended being a preventive agent for gynecomastia in these people. A double-blind research of 282 Males randomized to receive 20 mg of tamoxifen at the time daily with bical… Read More